Dachaigh › Melanoma Uveal › Tennessee
Sgrùdaidhean clionaigeach Melanoma Uveal ann an Tennessee
Tha 6 sgrùdaidhean airson Melanoma Uveal a’ lorg phàirtichean aig làraichean ann an Tennessee.
Bailtean ann an Tennessee
Teacsa sgrùdaidh oifigeil (Beurla)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Sarah Cannon Research Institute (SCRI), Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT07804186A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 15 Ògmh 2026 · NCT06940739Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Ògmh 2026 · NCT03947385Neoadjuvant Darovasertib in Primary Uveal Melanoma
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Cèit 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- agus 1 a bharrachd
A’ fastadhÌre 2/3
Gach aois · Gach gnè · Air ùrachadh 2 Gibl 2026 · NCT06581406Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
- SCRI Oncology Partners, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Samh 2025 · NCT07136181Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.